San Francisco, November 6th, 2019 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its it has rolled out its digital platform CardioCare throughout Europe to support its future clinical development programs in cardiovascular.
Read MoreRecardio at BIO Europe 2019
San Francisco, October 15, 2019 – Recardio Inc., a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases, announced that it was presenting at the BIO Europe in Hamburg.
Read MoreRecardio’s Phase 2 Regenerative Post-Myocardial Infarction Trial of Dutogliptin Now Enrolling and Recruiting in All Global Centers
San Francisco, September 9th, 2019 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction is now enrolling and recruiting in all multiple European and US centers.
Read MoreRecardio’s Phase 2 Regenerative Post-Myocardial Infarction Trial of Dutogliptin Enrolling and Recruiting in Global Centers
San Francisco, June 19, 2019 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction is now enrolling and recruiting in multiple European and US centers.
Read MoreFirst Closings of Series B Financing Round
San Francisco, June 3rd, 2019 – Recardio Inc., a clinical stage life science company developing regenerative therapies for cardiovascular diseases, announced the first closings of its Series B financing round.
Read More